Skip to main content

Morquio Syndrome: Drugs

Question for Department of Health

UIN 9950, tabled on 10 September 2015

To ask the Secretary of State for Health, when he expects NICE to announce its decision on approving the Vimizim form of elosulfase alfa.

Answered on

15 September 2015

The National Institute for Health and Care Excellence (NICE) published further draft guidance on 2 September 2015 which recommends elosulphase alfa (Vimizim) for the treatment of mucopolysaccharidosis (type IVA)/Morquio syndrome, subject to certain conditions. Interested parties now have until 23 September to comment on NICE’s draft recommendation.

NICE now expects to publish its final guidance in January 2016.

Answered by

Department of Health and Social Care
Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.